Division of Kirin Holdings Co. Ltd.
Latest From BioWa Inc.
Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.
In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.
AstraZeneca is looking at extending its alliance with Japan's Kyowa Hakko Kirin for a respiratory disease antibody, picking up an option to commercialize the interleukin-targeting therapy in Japan in a move that will extend the UK-based firm’s respiratory interests in this major market.
AstraZeneca highlighted pipeline progress during its quarterly earnings call, but remained on the defensive as analysts questioned two newly disclosed U.S. federal inquiries and the promotion of Marc Dunoyer to CFO, as the Big Pharma struggles with falling sales and profits.
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Kirin Holdings Co. Ltd.
- Senior Management
Yasunori Yamaguchi, PhD, Pres. & CEO
Masahiro Haro, CFO
Marc Silver, VP, Corp. Dev.
- Contact Info
Phone: (609) 580-7500
212 Carnegie Ctr.
Princeton, NJ 08540
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.